Core Viewpoint - Precision Medicine is set to debut on the Hong Kong Stock Exchange, aiming to raise approximately HKD 1.199 billion through the issuance of 27.7222 million shares at a price of HKD 43.24 per share, with trading expected to commence on January 8, 2026 [2][10]. Financial Performance - For the first half of 2025, Precision Medicine reported revenue of RMB 149 million and a gross profit of RMB 93.85 million [2][10]. Investment Background - Chengdu Mingsheng Investment Co., Ltd. invested RMB 5 million during the angel round, which has appreciated to RMB 675 million, yielding a remarkable return of 135 times over eight years [2][10]. - The company was founded in May 2017 and received its first investment four months later [3][10]. Shareholding Structure - As of the IPO, Chengdu Mingsheng holds 17.50464 million shares, representing 4.86% of the total shares, making it the fourth-largest shareholder [7][15]. - The major shareholders include Dr. Wang with 29.05% and Dr. Gao with 14.35% of the shares [15]. Future Prospects - The shares held by Chengdu Mingsheng are subject to a 12-month lock-up period post-IPO, with a market value of approximately HKD 757 million, equivalent to RMB 680 million [15].
成都一家公司“点石成金”：500万元天使轮投资，大赚6.75亿元